← Back to All US Stocks

Picard Medical, Inc. (PMI) Stock Fundamental Analysis & AI Rating 2026

PMI NYSE Surgical & Medical Instruments & Apparatus DE CIK: 0002030617
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 PMI Key Takeaways

Revenue: $4.9M
Net Margin: -546.6%
Free Cash Flow: $-15.7M
Current Ratio: 1.11x
Debt/Equity: 0.00x
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence
Picard Medical, Inc. (PMI) receives a STRONG SELL rating with 95% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $4.9M, net profit margin of -546.6%, and return on equity (ROE) of -712.6%, Picard Medical, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete PMI stock analysis for 2026.

Is Picard Medical, Inc. (PMI) a Good Investment?

Claude

Picard Medical exhibits severe operational distress with negative gross margins (-4.1%), catastrophic losses ($27M net loss on $4.9M revenue), and unsustainable cash burn ($15.7M annually). With only $7.5M cash and a current ratio of 1.11x, the company faces critical liquidity pressure within 6-12 months absent significant operational improvement or capital infusion. The negative gross margin indicates fundamental business model dysfunction rather than temporary startup scaling challenges.

Why Buy Picard Medical, Inc. Stock? PMI Key Strengths

Claude
  • + Revenue growth of 12.5% YoY demonstrates market demand for product
  • + Cash position of $7.5M provides short-term runway for turnaround efforts
  • + Zero long-term debt eliminates financial leverage burden

PMI Stock Risks: Picard Medical, Inc. Investment Risks

Claude
  • ! Negative gross margin of -4.1% reveals fundamental cost structure or pricing dysfunction
  • ! Annual cash burn of $15.7M against $7.5M cash creates existential solvency risk within 6 months
  • ! Net margin of -546.6% and operating margin of -268.4% indicate company is unsustainable in current form
  • ! Quick ratio of 0.72x below 1.0 threshold signals potential inability to meet short-term obligations
  • ! Zero insider Form 4 filings in 90 days suggests management lacks confidence in near-term recovery

Key Metrics to Watch

Claude
  • * Gross margin trajectory (critical inflection point for viability)
  • * Monthly cash burn rate and runway remaining
  • * Revenue growth sustainability and customer retention rates

Picard Medical, Inc. (PMI) Financial Metrics & Key Ratios

Revenue
$4.9M
Net Income
$-27.0M
EPS (Diluted)
$0.00
Free Cash Flow
$-15.7M
Total Assets
$22.5M
Cash Position
$7.5M

💡 AI Analyst Insight

Picard Medical, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

PMI Profit Margin, ROE & Profitability Analysis

Gross Margin -4.1%
Operating Margin -268.4%
Net Margin -546.6%
ROE -712.6%
ROA -119.8%
FCF Margin -317.3%

PMI vs Healthcare Sector: How Picard Medical, Inc. Compares

How Picard Medical, Inc. compares to Healthcare sector averages

Net Margin
PMI -546.6%
vs
Sector Avg 12.0%
PMI Sector
ROE
PMI -712.6%
vs
Sector Avg 15.0%
PMI Sector
Current Ratio
PMI 1.1x
vs
Sector Avg 2.0x
PMI Sector
Debt/Equity
PMI 0.0x
vs
Sector Avg 0.6x
PMI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Picard Medical, Inc. Stock Overvalued? PMI Valuation Analysis 2026

Based on fundamental analysis, Picard Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-712.6%
Sector avg: 15%
Net Profit Margin
-546.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Picard Medical, Inc. Balance Sheet: PMI Debt, Cash & Liquidity

Current Ratio
1.11x
Quick Ratio
0.72x
Debt/Equity
0.00x
Debt/Assets
83.2%
Interest Coverage
-4.45x
Long-term Debt
N/A

PMI Revenue & Earnings Growth: 5-Year Financial Trend

PMI 5-year financial data: Year 2025: Revenue $4.9M, Net Income -$21.1M, EPS $-2.99.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Picard Medical, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.99 indicates the company is currently unprofitable.

PMI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-317.3%
Free cash flow / Revenue

PMI Quarterly Earnings & Performance

Quarterly financial performance data for Picard Medical, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $881.0K -$2.0M $-0.19

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Picard Medical, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$15.7M
Cash generated from operations
Dividends
None
No dividend program

PMI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Picard Medical, Inc. (CIK: 0002030617)

📋 Recent SEC Filings

Date Form Document Action
Apr 13, 2026 8-K picardmedical_8k.htm View →
Mar 30, 2026 10-K pmi20251231_10k.htm View →
Mar 27, 2026 8-K picardmedical_8k.htm View →
Mar 25, 2026 8-K picardmedical_8k.htm View →
Mar 20, 2026 8-K picardmedical_8k.htm View →

Frequently Asked Questions about PMI

What is the AI rating for PMI?

Picard Medical, Inc. (PMI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PMI's key strengths?

Claude: Revenue growth of 12.5% YoY demonstrates market demand for product. Cash position of $7.5M provides short-term runway for turnaround efforts.

What are the risks of investing in PMI?

Claude: Negative gross margin of -4.1% reveals fundamental cost structure or pricing dysfunction. Annual cash burn of $15.7M against $7.5M cash creates existential solvency risk within 6 months.

What is PMI's revenue and growth?

Picard Medical, Inc. reported revenue of $4.9M.

Does PMI pay dividends?

Picard Medical, Inc. does not currently pay dividends.

Where can I find PMI SEC filings?

Official SEC filings for Picard Medical, Inc. (CIK: 0002030617) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PMI's EPS?

Picard Medical, Inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is PMI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Picard Medical, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is PMI stock overvalued or undervalued?

Valuation metrics for PMI: ROE of -712.6% (sector avg: 15%), net margin of -546.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy PMI stock in 2026?

Our dual AI analysis gives Picard Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PMI's free cash flow?

Picard Medical, Inc.'s operating cash flow is $-15.7M, with capital expenditures of N/A. FCF margin is -317.3%.

How does PMI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -546.6% (avg: 12%), ROE -712.6% (avg: 15%), current ratio 1.11 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI